{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T22:47:43Z","timestamp":1790549263942,"version":"4.1.0"},"reference-count":168,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,8,7]],"date-time":"2020-08-07T00:00:00Z","timestamp":1596758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2020.01283","type":"journal-article","created":{"date-parts":[[2020,8,7]],"date-time":"2020-08-07T05:26:49Z","timestamp":1596778009000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":67,"title":["Targeting the RANKL\/RANK\/OPG Axis for Cancer Therapy"],"prefix":"10.3389","volume":"10","author":[{"given":"Jie","family":"Ming","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shane J. F.","family":"Cronin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef M.","family":"Penninger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,8,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S0140-6736(00)49915-0","article-title":"The distribution of secondary growths in cancer of the breast","volume":"133","author":"Paget","year":"1889","journal-title":"Lancet."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e00366","DOI":"10.1042\/BSR20160150","article-title":"RANK-RANKL signalling in cancer","volume":"36","author":"Renema","year":"2016","journal-title":"Biosci Rep."},{"key":"B3","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ctrv.2017.10.010","article-title":"The anti-tumor effect of RANKL inhibition in malignant solid tumors - A systematic review","volume":"62","author":"de Groot","year":"2018","journal-title":"Cancer Treat Rev."},{"key":"B4","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/36593","article-title":"A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function","volume":"390","author":"Anderson","year":"1997","journal-title":"Nature."},{"key":"B5","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S0092-8674(00)80209-3","article-title":"Osteoprotegerin: a novel secreted protein involved in the regulation of bone density","volume":"89","author":"Simonet","year":"1997","journal-title":"Cell."},{"key":"B6","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/nm.4076","article-title":"LGR4 is a receptor for RANKL and negatively regulates osteoclast differentiation and bone resorption","volume":"22","author":"Luo","year":"2016","journal-title":"Nat Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"421746","DOI":"10.1155\/2015\/421746","article-title":"Biology of bone tissue: structure, function, and factors that influence bone cells","volume":"2015","author":"Florencio-Silva","year":"2015","journal-title":"BioMed Res Int."},{"key":"B8","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/S8756-3282(02)00953-5","article-title":"The effects of estrogen on osteoprotegerin, RANKL, and estrogen receptor expression in human osteoblasts","volume":"32","author":"Bord","year":"2003","journal-title":"Bone."},{"key":"B9","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1196\/annals.1443.016","article-title":"RANK\/RANKL: regulators of immune responses and bone physiology","volume":"1143","author":"Leibbrandt","year":"2008","journal-title":"Ann N Y Acad Sci."},{"key":"B10","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nature01658","article-title":"Osteoclast differentiation and activation","volume":"423","author":"Boyle","year":"2003","journal-title":"Nature."},{"key":"B11","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1177\/0022034513500306","article-title":"Advances in the regulation of osteoclasts and osteoclast functions","volume":"92","author":"Boyce","year":"2013","journal-title":"J Dent Res."},{"key":"B12","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","article-title":"Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation","volume":"93","author":"Lacey","year":"1998","journal-title":"Cell."},{"key":"B13","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1006\/bbrc.1998.9788","article-title":"RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis","volume":"253","author":"Nakagawa","year":"1998","journal-title":"Biochem Biophys Res Commun."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1084\/jem.186.12.2075","article-title":"TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor","volume":"186","author":"Wong","year":"1997","journal-title":"J Exp Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"25190","DOI":"10.1074\/jbc.272.40.25190","article-title":"TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells","volume":"272","author":"Wong","year":"1997","journal-title":"J Biol Chem."},{"key":"B16","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1006\/bbrc.1998.8586","article-title":"Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures","volume":"246","author":"Matsuzaki","year":"1998","journal-title":"Biochem Biophys Res Commun."},{"key":"B17","doi-asserted-by":"publisher","first-page":"4424","DOI":"10.1210\/endo.139.10.6331","article-title":"A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro","volume":"139","author":"Quinn","year":"1998","journal-title":"Endocrinology."},{"key":"B18","doi-asserted-by":"publisher","first-page":"3597","DOI":"10.1073\/pnas.95.7.3597","article-title":"Osteoclast differentiation factor is a ligand for osteoprotegerin\/osteoclastogenesis-inhibitory factor and is identical to TRANCE\/RANKL","volume":"95","author":"Yasuda","year":"1998","journal-title":"Proc Natl Acad Sci USA."},{"key":"B19","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1006\/bbrc.1999.0252","article-title":"A new member of tumor necrosis factor ligand family, ODF\/OPGL\/TRANCE\/RANKL, regulates osteoclast differentiation and function","volume":"256","author":"Takahashi","year":"1999","journal-title":"Biochem Biophys Res Commun."},{"key":"B20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/jbmr.5650140203","article-title":"Cell biology of paget's disease","volume":"14","author":"Reddy","year":"1999","journal-title":"J Bone Min Res."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1083\/jcb.142.5.1347","article-title":"Mode of action of interleukin-6 on mature osteoclasts. Novel interactions with extracellular Ca2+ sensing in the regulation of osteoclastic bone resorption","volume":"142","author":"Adebanjo","year":"1998","journal-title":"J Cell Biol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1084\/jem.191.2.275","article-title":"Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF\/RANKL-RANK interaction","volume":"191","author":"Kobayashi","year":"2000","journal-title":"J Exp Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1002\/jbmr.3142","article-title":"PTHrP(12-48) modulates the bone marrow microenvironment and suppresses human osteoclast differentiation and lifespan","volume":"32","author":"Kamalakar","year":"2017","journal-title":"J Bone Min Res."},{"key":"B24","doi-asserted-by":"publisher","first-page":"4367","DOI":"10.1210\/endo.140.9.7131","article-title":"Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells","volume":"140","author":"Hofbauer","year":"1999","journal-title":"Endocrinology."},{"key":"B25","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S8756-3282(99)00162-3","article-title":"Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells","volume":"25","author":"Hofbauer","year":"1999","journal-title":"Bone."},{"key":"B26","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/S8756-3282(03)00049-8","article-title":"Expression of RANK is dependent upon differentiation into the macrophage\/osteoclast lineage: induction by 1alpha, 25-dihydroxyvitamin D3 and TPA in a human myelomonocytic cell line, HL60","volume":"32","author":"Kido","year":"2003","journal-title":"Bone."},{"key":"B27","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1111\/odi.13013","article-title":"Local injection of RANKL facilitates tooth movement and alveolar bone remodeling","volume":"25","author":"Li","year":"2018","journal-title":"Oral Dis."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1359\/JBMR.050706","article-title":"Self-assembled RANK induces osteoclastogenesis ligand-independently","volume":"20","author":"Kanazawa","year":"2005","journal-title":"J Bone Min Res."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1038\/s41467-018-05244-y","article-title":"Soluble RANKL contributes to osteoclast formation in adult mice but not ovariectomy-induced bone loss","volume":"9","author":"Xiong","year":"2018","journal-title":"Nat Commun."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1210\/endo.139.3.5837","article-title":"Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG\/OCIF inhibits osteoclastogenesis in vitro","volume":"139","author":"Yasuda","year":"1998","journal-title":"Endocrinology."},{"key":"B31","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S0378-1119(97)00509-X","article-title":"Characterization of a novel TNF-like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and non-hematopoietic cells","volume":"204","author":"Tan","year":"1997","journal-title":"Gene."},{"key":"B32","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1006\/bbrc.1997.6603","article-title":"Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis","volume":"234","author":"Tsuda","year":"1997","journal-title":"Biochem Biophys Res Commun."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1101\/gad.12.9.1260","article-title":"osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification","volume":"12","author":"Bucay","year":"1998","journal-title":"Genes Dev."},{"key":"B34","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1096\/fasebj.12.10.845","article-title":"TR1, a new member of the tumor necrosis factor receptor superfamily, induces fibroblast proliferation and inhibits osteoclastogenesis and bone resorption","volume":"12","author":"Kwon","year":"1998","journal-title":"FASEB J."},{"key":"B35","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1006\/bbrc.1998.8697","article-title":"Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor\/osteoprotegerin","volume":"247","author":"Mizuno","year":"1998","journal-title":"Biochem Biophys Res Commun."},{"key":"B36","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1359\/jbmr.1998.13.5.763","article-title":"A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men","volume":"13","author":"Riggs","year":"1998","journal-title":"J Bone Min Res"},{"key":"B37","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/s41586-018-0482-7","article-title":"Coupling of bone resorption and formation by RANKL reverse signalling","volume":"561","author":"Ikebuchi","year":"2018","journal-title":"Nature."},{"key":"B38","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1210\/jc.2017-02669","article-title":"Effects of long-term denosumab on bone histomorphometry and mineralization in women with postmenopausal osteoporosis","volume":"103","author":"Dempster","year":"2018","journal-title":"J Clin Endocrinol Metab."},{"key":"B39","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/S1470-2045(18)30072-X","article-title":"Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study","volume":"19","author":"Raje","year":"2018","journal-title":"Lancet Oncol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1111\/ajt.13692","article-title":"Effect of twice-yearly denosumab on prevention of bone mineral density loss in de novo kidney transplant recipients: a randomized controlled trial","volume":"16","author":"Bonani","year":"2016","journal-title":"Am J Transpl."},{"key":"B41","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s00223-018-0394-4","article-title":"Bone mineral density changes after 1 year of denosumab discontinuation in postmenopausal women with long-term denosumab treatment for osteoporosis","volume":"103","author":"Popp","year":"2018","journal-title":"Calcif Tissue Int."},{"key":"B42","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/S2213-8587(18)30075-5","article-title":"Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study","volume":"6","author":"Saag","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s00774-017-0848-1","article-title":"Effects of denosumab treatment on bone mineral density and joint destruction in patients with rheumatoid arthritis","volume":"36","author":"Mochizuki","year":"2018","journal-title":"J Bone Min Metab."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","article-title":"Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-switch study): extension of a randomised controlled trial","volume":"386","author":"Leder","year":"2015","journal-title":"Lancet."},{"key":"B46","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.4049\/jimmunol.162.5.2562","article-title":"TRANCE, a TNF family member, is differentially expressed on T cell subsets and induces cytokine production in dendritic cells","volume":"162","author":"Josien","year":"1999","journal-title":"J Immunol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1101\/gad.13.18.2412","article-title":"RANK is essential for osteoclast and lymph node development","volume":"13","author":"Dougall","year":"1999","journal-title":"Genes Dev."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1084\/jem.192.10.1467","article-title":"Regulation of peripheral lymph node genesis by the tumor necrosis factor family member TRANCE","volume":"192","author":"Kim","year":"2000","journal-title":"J Exp Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/16852","article-title":"OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis","volume":"397","author":"Kong","year":"1999","journal-title":"Nature."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1016\/j.ajpath.2011.06.004","article-title":"Distinct developmental requirements for isolated lymphoid follicle formation in the small and large intestine: RANKL is essential only in the small intestine","volume":"179","author":"Knoop","year":"2011","journal-title":"Am J Pathol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4049\/jimmunol.174.1.21","article-title":"Cellular interactions in lymph node development","volume":"174","author":"Cupedo","year":"2005","journal-title":"J Immunol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/S1074-7613(02)00479-X","article-title":"Different cytokines induce surface lymphotoxin-alphabeta on IL-7 receptor-alpha cells that differentially engender lymph nodes and Peyer's patches","volume":"17","author":"Yoshida","year":"2002","journal-title":"Immunity."},{"key":"B53","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1093\/intimm\/dxs002","article-title":"Expression pattern changes and function of RANKL during mouse lymph node microarchitecture development","volume":"24","author":"Sugiyama","year":"2012","journal-title":"Int Immunol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"261","DOI":"10.3389\/fimmu.2012.00261","article-title":"Emerging functions of RANKL in lymphoid tissues","volume":"3","author":"Mueller","year":"2012","journal-title":"Front Immunol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1084\/jem.20062497","article-title":"RANK signals from CD4+3\u2212 inducer cells regulate development of Aire-expressing epithelial cells in the thymic medulla","volume":"204","author":"Rossi","year":"2007","journal-title":"J Exp Med."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/j.immuni.2019.05.008","article-title":"Lymph node mesenchymal and endothelial stromal cells cooperate via the RANK-RANKL cytokine axis to shape the sinusoidal macrophage niche","volume":"50","author":"Camara","year":"2019","journal-title":"Immunity."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/j.immuni.2018.04.012","article-title":"The tumor necrosis factor superfamily member RANKL suppresses effector cytokine production in group 3 innate lymphoid cells","volume":"48","author":"Bando","year":"2018","journal-title":"Immunity."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.4049\/jimmunol.1102063","article-title":"Development and function of murine B cells lacking RANK","volume":"188","author":"Perlot","year":"2012","journal-title":"J Immunol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jsbmb.2013.09.008","article-title":"Prevention and treatment of postmenopausal osteoporosis","volume":"142","author":"Tella","year":"2014","journal-title":"J Steroid Biochem Mol Biol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"29851","DOI":"10.1074\/jbc.M112.377945","article-title":"Receptor activator of nuclear factor kappaB ligand (RANKL) protein expression by B lymphocytes contributes to ovariectomy-induced bone loss","volume":"287","author":"Onal","year":"2012","journal-title":"J Biol Chem."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1038\/nm1518","article-title":"Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells","volume":"12","author":"Loser","year":"2006","journal-title":"Nat Med."},{"key":"B62","doi-asserted-by":"publisher","first-page":"5738","DOI":"10.4049\/jimmunol.0901563","article-title":"RANKL is necessary and sufficient to initiate development of antigen-sampling M cells in the intestinal epithelium","volume":"183","author":"Knoop","year":"2009","journal-title":"J Immunol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1038\/mi.2015.121","article-title":"Antigen sampling by intestinal M cells is the principal pathway initiating mucosal IgA production to commensal enteric bacteria","volume":"9","author":"Rios","year":"2016","journal-title":"Mucosal Immunol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/ni.3732","article-title":"Identification of subepithelial mesenchymal cells that induce IgA and diversify gut microbiota","volume":"18","author":"Nagashima","year":"2017","journal-title":"Nat Immunol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1172\/JCI11066","article-title":"Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha","volume":"106","author":"Cenci","year":"2000","journal-title":"J Clin Invest."},{"key":"B66","doi-asserted-by":"publisher","first-page":"13960","DOI":"10.1073\/pnas.251534698","article-title":"Up-regulation of TNF-producing T cells in the bone marrow: a key mechanism by which estrogen deficiency induces bone loss in vivo","volume":"98","author":"Roggia","year":"2001","journal-title":"Proc Natl Acad Sci USA."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1359\/jbmr.060726","article-title":"T lymphocyte-deficient mice lose trabecular bone mass with ovariectomy","volume":"21","author":"Lee","year":"2006","journal-title":"J Bone Min Res."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1172\/JCI200317215","article-title":"Role of RANK ligand in mediating increased bone resorption in early postmenopausal women","volume":"111","author":"Eghbali-Fatourechi","year":"2003","journal-title":"J Clin Invest."},{"key":"B69","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.bone.2008.02.017","article-title":"Estrogen deficiency increases osteoclastogenesis up-regulating T cells activity: a key mechanism in osteoporosis","volume":"43","author":"D'Amelio","year":"2008","journal-title":"Bone."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1002\/jcb.21121","article-title":"Ovariectomy-induced bone loss occurs independently of B cells","volume":"100","author":"Li","year":"2007","journal-title":"J Cell Biochem."},{"key":"B71","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","article-title":"Cancer statistics","volume":"68","author":"Siegel","year":"2018","journal-title":"Cancer J Clin."},{"key":"B72","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/S0140-6736(03)14065-2","article-title":"Breast cancer and hormone-replacement therapy in the million women study","volume":"362","author":"Beral","year":"2003","journal-title":"Lancet."},{"key":"B73","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA."},{"key":"B74","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1001\/jama.2017.11217","article-title":"Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the women's health initiative randomized trials","volume":"318","author":"Manson","year":"2017","journal-title":"JAMA."},{"key":"B75","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1001\/jama.2013.278040","article-title":"Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the women's health initiative randomized trials","volume":"310","author":"Manson","year":"2013","journal-title":"JAMA."},{"key":"B76","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0092-8674(00)00103-3","article-title":"The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development","volume":"103","author":"Fata","year":"2000","journal-title":"Cell."},{"key":"B77","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1128\/MCB.01298-06","article-title":"RANK overexpression in transgenic mice with mouse mammary tumor virus promoter-controlled RANK increases proliferation and impairs alveolar differentiation in the mammary epithelia and disrupts lumen formation in cultured epithelial acini","volume":"27","author":"Gonzalez-Suarez","year":"2007","journal-title":"Mol Cell Biol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/nature09027","article-title":"Control of mammary stem cell function by steroid hormone signalling","volume":"465","author":"Asselin-Labat","year":"2010","journal-title":"Nature."},{"key":"B79","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/nature09091","article-title":"Progesterone induces adult mammary stem cell expansion","volume":"465","author":"Joshi","year":"2010","journal-title":"Nature."},{"key":"B80","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.stemcr.2015.05.012","article-title":"RANK signaling amplifies WNT-responsive mammary progenitors through R-SPONDIN1","volume":"5","author":"Joshi","year":"2015","journal-title":"Stem Cell Rep."},{"key":"B81","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.tcb.2017.11.001","article-title":"RANKL and RANK: from mammalian physiology to cancer treatment","volume":"28","author":"Rao","year":"2018","journal-title":"Trends Cell Biol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"3811","DOI":"10.18632\/oncotarget.14013","article-title":"Aberrant regulation of RANKL\/OPG in women at high risk of developing breast cancer","volume":"8","author":"Kiechl","year":"2017","journal-title":"Oncotarget."},{"key":"B83","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1158\/1940-6207.CAPR-17-0125","article-title":"Circulating RANKL and RANKL\/OPG and breast cancer risk by ER and PR subtype: results from the EPIC cohort","volume":"10","author":"Sarink","year":"2017","journal-title":"Cancer Prev Res."},{"key":"B84","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/nature09387","article-title":"Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer","volume":"468","author":"Schramek","year":"2010","journal-title":"Nature."},{"key":"B85","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/S0092-8674(01)00599-2","article-title":"IKKalpha provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development","volume":"107","author":"Cao","year":"2001","journal-title":"Cell."},{"key":"B86","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/nature09495","article-title":"RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis","volume":"468","author":"Gonzalez-Suarez","year":"2010","journal-title":"Nature."},{"key":"B87","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1016\/S1470-2045(13)70448-0","article-title":"The sex hormone system in carriers of BRCA1\/2 mutations: a case-control study","volume":"14","author":"Widschwendter","year":"2013","journal-title":"Lancet Oncol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1016\/j.ebiom.2015.08.037","article-title":"Osteoprotegerin (OPG), the endogenous inhibitor of receptor activator of NF-kappaB ligand (RANKL), is dysregulated in BRCA mutation carriers","volume":"2","author":"Widschwendter","year":"2015","journal-title":"EBioMedicine."},{"key":"B89","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s10585-007-9127-1","article-title":"Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis","volume":"25","author":"Canon","year":"2008","journal-title":"Clin Exp Metast."},{"key":"B90","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/cr.2016.69","article-title":"RANKL\/RANK control Brca1 mutation","volume":"26","author":"Sigl","year":"2016","journal-title":"Cell Res."},{"key":"B91","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1038\/nm.4118","article-title":"RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers","volume":"22","author":"Nolan","year":"2016","journal-title":"Nat Med."},{"key":"B92","volume-title":"ClinicalTrials.gov-NCT03382574","year":"2018"},{"key":"B93","volume-title":"ClinicalTrials.gov-NCT01864798","year":"2018"},{"key":"B94","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1158\/1538-7445.AM2018-CT101","article-title":"D-BEYOND: a window of opportunity trial evaluating denosumab, a RANK-ligand (RANKL) inhibitor and its biological effects in young pre-menopausal women diagnosed with early breast cancer [abstract]","author":"Nguyen","year":"2018","journal-title":"Cancer Res"},{"key":"B95","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1038\/cr.2008.84","article-title":"Receptor activator of NF-kappaB Ligand (RANKL) expression is associated with epithelial to mesenchymal transition in human prostate cancer cells","volume":"18","author":"Odero-Marah","year":"2008","journal-title":"Cell Res."},{"key":"B96","doi-asserted-by":"publisher","first-page":"2845","DOI":"10.1016\/j.ajpath.2011.02.003","article-title":"RANKL expression specifically observed in vivo promotes epithelial mesenchymal transition and tumor progression","volume":"178","author":"Yamada","year":"2011","journal-title":"Am J Pathol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1158\/0008-5472.CAN-12-0044","article-title":"RANK induces epithelial-mesenchymal transition and stemness in human mammary epithelial cells and promotes tumorigenesis and metastasis","volume":"72","author":"Palafox","year":"2012","journal-title":"Cancer Res."},{"key":"B98","doi-asserted-by":"publisher","first-page":"25328","DOI":"10.18632\/oncotarget.8291","article-title":"CCL20 mediates RANK\/RANKL-induced epithelial-mesenchymal transition in endometrial cancer cells","volume":"7","author":"Liu","year":"2016","journal-title":"Oncotarget."},{"key":"B99","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1101\/gad.304162.117","article-title":"RANK rewires energy homeostasis in lung cancer cells and drives primary lung cancer","volume":"31","author":"Rao","year":"2017","journal-title":"Genes Dev."},{"key":"B100","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1097\/JTO.0b013e31826aec2b","article-title":"Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study","volume":"7","author":"Scagliotti","year":"2012","journal-title":"J Thor Oncol."},{"key":"B101","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1200\/JCO.2009.25.9739","article-title":"Lung cancer and hormone replacement therapy: association in the vitamins and lifestyle study","volume":"28","author":"Slatore","year":"2010","journal-title":"J Clin Oncol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1158\/1055-9965.EPI-10-0450","article-title":"Reproductive factors, hormone use, and risk for lung cancer in postmenopausal women, the nurses' health study","volume":"19","author":"Baik","year":"2010","journal-title":"Cancer Epidemiol Biomark Prev."},{"key":"B103","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s12094-013-1137-7","article-title":"Lung cancer in women: an overview with special focus on Spanish women","volume":"16","author":"Remon","year":"2014","journal-title":"Clin Transl Oncol."},{"key":"B104","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1002\/jcb.23009","article-title":"RANKL increases migration of human lung cancer cells through intercellular adhesion molecule-1 up-regulation","volume":"112","author":"Chen","year":"2011","journal-title":"J Cell Biochem."},{"key":"B105","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.3892\/or.2014.3511","article-title":"Potential role of the OPG\/RANK\/RANKL axis in prostate cancer invasion and bone metastasis","volume":"32","author":"Li","year":"2014","journal-title":"Oncol Rep."},{"key":"B106","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s00262-011-0974-x","article-title":"Interaction between the skeletal and immune systems in cancer: mechanisms and clinical implications","volume":"60","author":"Terpos","year":"2011","journal-title":"Cancer Immunol Immunother."},{"key":"B107","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/nrc3910","article-title":"Metastasis prevention by targeting the dormant niche","volume":"15","author":"Ghajar","year":"2015","journal-title":"Nat Rev Cancer."},{"key":"B108","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/nrc.2016.44","article-title":"Bone metastasis: the importance of the neighbourhood","volume":"16","author":"Croucher","year":"2016","journal-title":"Nat Rev Cancer."},{"key":"B109","doi-asserted-by":"publisher","first-page":"20200","DOI":"10.1074\/jbc.RA118.004751","article-title":"Parathyroid hormone(1-34) and its analogs differentially modulate osteoblastic Rankl expression via PKA\/SIK2\/SIK3 and PP1\/PP2A-CRTC3 signaling","volume":"293","author":"Ricarte","year":"2018","journal-title":"J Biol Chem."},{"key":"B110","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.4049\/jimmunol.145.10.3297","article-title":"IL-6 is produced by osteoblasts and induces bone resorption","volume":"145","author":"Ishimi","year":"1990","journal-title":"J Immunol."},{"key":"B111","doi-asserted-by":"publisher","first-page":"595","DOI":"10.4049\/jimmunol.1601528","article-title":"IL-3 Differentially regulates membrane and soluble RANKL in osteoblasts through metalloproteases and the JAK2\/STAT5 pathway and improves the RANKL\/OPG ratio in adult mice","volume":"200","author":"Singh","year":"2018","journal-title":"J Immunol."},{"key":"B112","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1159\/000465455","article-title":"IL-6 enhances osteocyte-mediated osteoclastogenesis by promoting JAK2 and RANKL activity in vitro","volume":"41","author":"Wu","year":"2017","journal-title":"Cell Physiol Biochem."},{"key":"B113","doi-asserted-by":"publisher","first-page":"5200","DOI":"10.12659\/MSM.909720","article-title":"Gene modification of transforming growth factor beta (TGF-beta) and interleukin 10 (IL-10) in suppressing Mt sonicate induced osteoclast formation and bone absorption","volume":"24","author":"Yi","year":"2018","journal-title":"Med Sci Monit."},{"key":"B114","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.biopha.2018.03.080","article-title":"TNF-alpha contributes to postmenopausal osteoporosis by synergistically promoting RANKL-induced osteoclast formation","volume":"102","author":"Zha","year":"2018","journal-title":"Biomed Pharmacother Biomed Pharmacother."},{"key":"B115","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.yexcr.2017.08.003","article-title":"Neuromedin B and its receptor silencing suppresses osteoclast generation by modulating precursor proliferation via M-CSF\/c-Fms\/D-type cyclins","volume":"359","author":"Yeo","year":"2017","journal-title":"Exp Cell Res."},{"key":"B116","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/j.cellsig.2016.05.018","article-title":"Follistatin-like 1 promotes osteoclast formation via RANKL-mediated NF-kappaB activation and M-CSF-induced precursor proliferation","volume":"28","author":"Kim","year":"2016","journal-title":"Cell Signal."},{"key":"B117","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1111\/jcmm.12814","article-title":"Aminothiazoles inhibit RANKL- and LPS-mediated osteoclastogenesis and PGE2 production in RAW 264","volume":"20","author":"Kats","year":"2016","journal-title":"J Cell Mol Med."},{"key":"B118","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1210\/en.2018-00574","article-title":"Diabetes, obesity, and breast cancer","volume":"159","author":"Kang","year":"2018","journal-title":"Endocrinology."},{"key":"B119","doi-asserted-by":"publisher","first-page":"R253","DOI":"10.1530\/ERC-15-0135","article-title":"Insulin and IGFs in renal cancer risk and progression","volume":"22","author":"Solarek","year":"2015","journal-title":"Endocr-Relat Cancer."},{"key":"B120","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.pharmthera.2017.05.013","article-title":"Fibroblast growth factors (FGFs) in cancer: FGF traps as a new therapeutic approach","volume":"179","author":"Presta","year":"2017","journal-title":"Pharmacol Ther."},{"key":"B121","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1159\/000493286","article-title":"FGF18 enhances migration and the epithelial-mesenchymal transition in breast cancer by regulating Akt\/GSK3beta\/Beta-catenin signaling","volume":"49","author":"Song","year":"2018","journal-title":"Cell Physiol Biochem."},{"key":"B122","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/nature25010","article-title":"Structures of beta-klotho reveal a 'zip code'-like mechanism for endocrine FGF signalling","volume":"553","author":"Lee","year":"2018","journal-title":"Nature."},{"key":"B123","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s10549-018-4664-7","article-title":"The PDGF pathway in breast cancer is linked to tumour aggressiveness, triple-negative subtype and early recurrence","volume":"169","author":"Jansson","year":"2018","journal-title":"Breast Cancer Res Treat."},{"key":"B124","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.bbrc.2018.06.106","article-title":"PDGF family function and prognostic value in tumor biology","volume":"503","author":"Bartoschek","year":"2018","journal-title":"Biochem Biophys Res Commun."},{"key":"B125","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.3390\/cells8101130","article-title":"The interactivity between TGFbeta and BMP signaling in organogenesis, fibrosis, and cancer","volume":"8","author":"Dituri","year":"2019","journal-title":"Cells."},{"key":"B126","doi-asserted-by":"publisher","first-page":"4013","DOI":"10.1038\/s41388-018-0243-y","article-title":"Contribution of three-dimensional architecture and tumor-associated fibroblasts to hepcidin regulation in breast cancer","volume":"37","author":"Blanchette-Farra","year":"2018","journal-title":"Oncogene."},{"key":"B127","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.3892\/or.2019.7275","article-title":"High expression of bone morphogenetic protein (BMP) 6 and BMP7 are associated with higher immune cell infiltration and better survival in estrogen receptorpositive breast cancer","volume":"42","author":"Katsuta","year":"2019","journal-title":"Oncol Rep."},{"key":"B128","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ctrv.2014.12.001","article-title":"Crosstalk between bone niche and immune system: osteoimmunology signaling as a potential target for cancer treatment","volume":"41","author":"Criscitiello","year":"2015","journal-title":"Cancer Treat Rev."},{"key":"B129","doi-asserted-by":"publisher","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J Clin Oncol."},{"key":"B130","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet."},{"key":"B131","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J Clin Oncol."},{"key":"B132","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1038\/nature04524","article-title":"Regulation of cancer cell migration and bone metastasis by RANKL","volume":"440","author":"Jones","year":"2006","journal-title":"Nature."},{"key":"B133","doi-asserted-by":"publisher","first-page":"e0185736","DOI":"10.1371\/journal.pone.0185736","article-title":"Breast cancer cell-derived fibroblast growth factors enhance osteoclast activity and contribute to the formation of metastatic lesions","volume":"12","author":"Aukes","year":"2017","journal-title":"PLoS ONE."},{"key":"B134","doi-asserted-by":"publisher","first-page":"100244","DOI":"10.1016\/j.jbo.2019.100244","article-title":"The bone metastasis niche in breast cancer-potential overlap with the haematopoietic stem cell niche in vivo","volume":"17","author":"Allocca","year":"2019","journal-title":"J Bone Oncol."},{"key":"B135","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12964-018-0259-5","article-title":"Reawakening of dormant estrogen-dependent human breast cancer cells by bone marrow stroma secretory senescence","volume":"16","author":"Tivari","year":"2018","journal-title":"Cell Commun Signal."},{"key":"B136","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.bone.2006.11.006","article-title":"DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process","volume":"40","author":"Mori","year":"2007","journal-title":"Bone."},{"key":"B137","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1530\/ERC-14-0199","article-title":"Castration-induced bone loss triggers growth of disseminated prostate cancer cells in bone","volume":"21","author":"Ottewell","year":"2014","journal-title":"Endocr-Relat Cancer."},{"key":"B138","doi-asserted-by":"publisher","first-page":"18635","DOI":"10.1038\/s41598-019-54566-4","article-title":"Bone secreted factors induce cellular quiescence in prostate cancer cells","volume":"9","author":"Yu-Lee","year":"2019","journal-title":"Sci Rep."},{"key":"B139","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.bcp.2019.05.005","article-title":"Thrombospondin enhances RANKL-dependent osteoclastogenesis and facilitates lung cancer bone metastasis","volume":"166","author":"Wang","year":"2019","journal-title":"Biochem Pharmacol."},{"key":"B140","doi-asserted-by":"publisher","first-page":"799","DOI":"10.3892\/or.2014.3651","article-title":"MPA influences tumor cell proliferation, migration, and invasion induced by RANKL through PRB involving the MAPK pathway in endometrial cancer","volume":"33","author":"Wang","year":"2015","journal-title":"Oncol Rep."},{"key":"B141","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1038\/sj.emboj.7600564","article-title":"RANK-mediated amplification of TRAF6 signaling leads to NFATc1 induction during osteoclastogenesis","volume":"24","author":"Gohda","year":"2005","journal-title":"EMBO J."},{"key":"B142","doi-asserted-by":"publisher","first-page":"44347","DOI":"10.1074\/jbc.M202009200","article-title":"A RANK\/TRAF6-dependent signal transduction pathway is essential for osteoclast cytoskeletal organization and resorptive function","volume":"277","author":"Armstrong","year":"2002","journal-title":"J Biol Chem."},{"key":"B143","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s41232-019-0111-3","article-title":"RANKL biology: bone metabolism, the immune system, and beyond","volume":"40","author":"Ono","year":"2020","journal-title":"Inflamm Regen."},{"key":"B144","doi-asserted-by":"publisher","first-page":"6799","DOI":"10.1074\/jbc.M109434200","article-title":"TNF-related activation-induced cytokine (TRANCE) induces angiogenesis through the activation of Src and phospholipase C (PLC) in human endothelial cells","volume":"277","author":"Kim","year":"2002","journal-title":"J Biol Chem."},{"key":"B145","doi-asserted-by":"publisher","first-page":"39548","DOI":"10.1074\/jbc.M300539200","article-title":"Vascular endothelial growth factor up-regulates expression of receptor activator of NF-kappa B (RANK) in endothelial cells. Concomitant increase of angiogenic responses to RANK ligand","volume":"278","author":"Min","year":"2003","journal-title":"J Biol Chem."},{"key":"B146","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1096\/fj.03-0215fje","article-title":"RANKL regulates endothelial cell survival through the phosphatidylinositol 3'-kinase\/Akt signal transduction pathway","volume":"17","author":"Kim","year":"2003","journal-title":"FASEB J."},{"key":"B147","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1111\/j.1538-7836.2011.04207.x","article-title":"Osteoprotegerin, a new actor in vasculogenesis, stimulates endothelial colony-forming cells properties","volume":"9","author":"Benslimane-Ahmim","year":"2011","journal-title":"J Thromb Haemost."},{"key":"B148","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/nature09707","article-title":"Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling","volume":"470","author":"Tan","year":"2011","journal-title":"Nature."},{"key":"B149","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.1038\/jid.2015.209","article-title":"Receptor activator of NF-kappaB ligand promotes the production of CCL17 from RANK+ M2 macrophages","volume":"135","author":"Fujimura","year":"2015","journal-title":"J Invest Dermatol."},{"key":"B150","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1038\/s41388-018-0579-3","article-title":"ERRalpha promotes breast cancer cell dissemination to bone by increasing RANK expression in primary breast tumors","volume":"38","author":"Vargas","year":"2018","journal-title":"Oncogene."},{"key":"B151","doi-asserted-by":"publisher","first-page":"clincanres.2482.2018","DOI":"10.1158\/1078-0432.CCR-18-2482","article-title":"Prognostic value of RANKL\/OPG serum levels and disseminated tumor cells in non-metastatic breast cancer","volume":"25","author":"Rachner","year":"2018","journal-title":"Clin Cancer Res."},{"key":"B152","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/S1470-2045(18)30862-3","article-title":"Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Gnant","year":"2019","journal-title":"Lancet Oncol."},{"key":"B153","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/S1470-2045(19)30687-4","article-title":"Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial","volume":"21","author":"Coleman","year":"2019","journal-title":"Lancet Oncol."},{"key":"B154","doi-asserted-by":"publisher","first-page":"e79","DOI":"10.1097\/JTO.0b013e318293e443","article-title":"Why denosumab obtains a survival benefit over zoledronic acid in bone metastatic lung cancer patients?","volume":"8","author":"Deiana","year":"2013","journal-title":"J Thorac Oncol."},{"key":"B155","doi-asserted-by":"publisher","first-page":"e01081","DOI":"10.1002\/cti2.1081","article-title":"Dual targeting of RANKL and PD-1 with a bispecific antibody improves anti-tumor immunity","volume":"8","author":"Dougall","year":"2019","journal-title":"Clin Transl Immunol."},{"key":"B156","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.bone.2013.10.024","article-title":"Bisphosphonate-osteoclasts: changes in osteoclast morphology and function induced by antiresorptive nitrogen-containing bisphosphonate treatment in osteoporosis patients","volume":"59","author":"Jobke","year":"2014","journal-title":"Bone."},{"key":"B157","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ctrv.2018.04.014","article-title":"The role of bisphosphonates or denosumab in light of the availability of new therapies for prostate cancer","volume":"68","author":"Saad","year":"2018","journal-title":"Cancer Treat Rev."},{"key":"B158","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/S0140-6736(15)60995-3","article-title":"Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"386","author":"Gnant","year":"2015","journal-title":"Lancet."},{"key":"B159","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1158\/1538-7445.SABCS15-S2-02","article-title":"The impact of adjuvant denosumab on disease-free survival: results from 3,425 postmenopausal patients of the ABCSG-18 trial [abstract]","author":"Gnant","year":"2016","journal-title":"Cancer Res"},{"key":"B160","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ctrv.2016.11.007","article-title":"Resistance to PD1\/PDL1 checkpoint inhibition","volume":"52","author":"O'Donnell","year":"2017","journal-title":"Cancer Treat Rev."},{"key":"B161","doi-asserted-by":"publisher","first-page":"e1431088","DOI":"10.1080\/2162402X.2018.1431088","article-title":"RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer","volume":"7","author":"Ahern","year":"2018","journal-title":"Oncoimmunology."},{"key":"B162","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/nrclinonc.2015.209","article-title":"Combination cancer immunotherapies tailored to the tumour microenvironment","volume":"13","author":"Smyth","year":"2016","journal-title":"Nat Rev Clin Oncol."},{"key":"B163","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40425-015-0064-2","article-title":"Rapid complete response of metastatic melanoma in a patient undergoing ipilimumab immunotherapy in the setting of active ulcerative colitis","volume":"3","author":"Bostwick","year":"2015","journal-title":"J Immunother Cancer."},{"key":"B164","doi-asserted-by":"publisher","first-page":"e1480301","DOI":"10.1080\/2162402X.2018.1480301","article-title":"An observational study of concomitant immunotherapies and denosumab in patients with advanced melanoma or lung cancer","volume":"7","author":"Liede","year":"2018","journal-title":"Oncoimmunology."},{"key":"B165","doi-asserted-by":"publisher","first-page":"5789","DOI":"10.1158\/1078-0432.CCR-17-0606","article-title":"Co-administration of RANKL and CTLA4 antibodies enhances lymphocyte-mediated antitumor immunity in mice","volume":"23","author":"Ahern","year":"2017","journal-title":"Clin Cancer Res."},{"key":"B166","doi-asserted-by":"publisher","first-page":"e104","DOI":"10.1200\/JCO.2013.51.3572","article-title":"Combination anti-CTLA-4 and anti-RANKL in metastatic melanoma","volume":"34","author":"Smyth","year":"2016","journal-title":"J Clin Oncol."},{"key":"B167","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1007\/s12020-015-0723-6","article-title":"Effects of denosumab on peripheral lymphocyte subpopulations","volume":"53","author":"Rossini","year":"2016","journal-title":"Endocrine."},{"key":"B168","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1084\/jem.20131889","article-title":"Enhancement of an anti-tumor immune response by transient blockade of central T cell tolerance","volume":"211","author":"Khan","year":"2014","journal-title":"J Exp Med."}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.01283\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T11:18:40Z","timestamp":1696504720000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.01283\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,7]]},"references-count":168,"alternative-id":["10.3389\/fonc.2020.01283"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2020.01283","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,7]]},"article-number":"1283"}}